专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20060276474A1 Novel carboxylic acid derivatives, their preparation and use 失效
标题翻译：新型羧酸衍生物，其制备和用途
公开(公告)号：US20060276474A1
公开(公告)日：2006-12-07
申请号：US11502293
申请日：2006-08-10
申请人： Hartmut Riechers , Dagmar Klinge , Wilhelm Amberg , Andreas Kling , Stefan Muller , Ernst Baumann , Joachim Rheinheimer , Uwe Vogelbacher , Wolfgang Wernet , Liliane Unger , Manfred Raschack
发明人： Hartmut Riechers , Dagmar Klinge , Wilhelm Amberg , Andreas Kling , Stefan Muller , Ernst Baumann , Joachim Rheinheimer , Uwe Vogelbacher , Wolfgang Wernet , Liliane Unger , Manfred Raschack
IPC分类号： C07D251/48 , A61K31/53 , A61K31/513
CPC分类号： C07D495/04 , C07D239/34 , C07D239/48 , C07D239/52 , C07D239/60 , C07D239/70 , C07D239/96 , C07D251/20 , C07D251/26 , C07D251/52 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D491/04 , C07D491/048
摘要： Carboxylic acid derivatives where R-R6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.
摘要翻译：其中R-R 6，X，Y和Z具有说明书中所述含义及其制备的羧酸衍生物。新型化合物适用于控制疾病。

22. 发明授权

US07098212B2 Piperazine derivatives 失效
标题翻译：哌嗪衍生物
公开(公告)号：US07098212B2
公开(公告)日：2006-08-29
申请号：US10273658
申请日：2002-10-18
申请人： Laura C. Blumberg , Matthew F. Brown , Matthew M. Hayward , Gregory D. Lundquist , Christopher S. Poss , Andrei Shavnya
发明人： Laura C. Blumberg , Matthew F. Brown , Matthew M. Hayward , Gregory D. Lundquist , Christopher S. Poss , Andrei Shavnya
IPC分类号： A61K31/506 , A61K31/495 , A61K31/496 , C07D295/00 , C07D403/12
CPC分类号： C07D213/74 , C07D207/16 , C07D213/63 , C07D213/64 , C07D213/75 , C07D213/76 , C07D213/79 , C07D213/80 , C07D213/82 , C07D239/34 , C07D239/60 , C07D257/04 , C07D277/56 , C07D295/185 , C07D307/33 , C07D307/68 , C07D333/38
摘要： The present invention relates to compounds of the formula I and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R1, R2, R3, R4 and R5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.
摘要翻译：本发明涉及式I化合物及其药学上可接受的形式; 其中X，Y，a，b，c，d，R 1，R 2，R 3，R 4， SUP＆gt;和R 5＆gt;如本文所定义。此外，本发明还涉及包含式I化合物和药学上可接受的载体的药物组合物。此外，本发明涉及使用本文所述的化合物和组合物治疗或预防可通过拮抗哺乳动物CCR1受体来治疗或预防的病症或病症的方法。

23. 发明授权

US07074925B1 N-substituted derivatives of 5-oxyiminobarbituric acid 失效
标题翻译： 5-氧亚氨基巴比妥酸的N-取代衍生物
公开(公告)号：US07074925B1
公开(公告)日：2006-07-11
申请号：US09701204
申请日：1998-05-26
申请人： Rimma Lliinichna Ashkinazi
发明人： Rimma Lliinichna Ashkinazi
IPC分类号： C07D239/52 , A01K31/505 , A01P31/22
CPC分类号： C07D239/66 , C07D239/60
摘要： N-substituted derivatives of 5-oximinobarbituric add of the general formula where X is sulfur; R1 is selected from the group consisting of saturated or unsaturated alkyl, cycloalkyl, aryl and arylalkyl; and R2 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, cycloalkyl, aryl and arylalkyl possessing a biological activity.
摘要翻译：其中X为硫的通式为5-氧亚氨基巴比妥酸的N-取代衍生物; R 1选自饱和或不饱和的烷基，环烷基，芳基和芳基烷基; R 2选自具有生物活性的氢，饱和或不饱和的烷基，环烷基，芳基和芳基烷基。

24. 发明授权

US07018960B2 Lubricant composition, method for using and preparing thereof and molecular complex compound used for the same 失效
标题翻译：润滑剂组合物，其使用及其制备方法和用于其的分子复合化合物
公开(公告)号：US07018960B2
公开(公告)日：2006-03-28
申请号：US10163605
申请日：2002-06-07
申请人： Masayuki Negoro , Ken Kawata
发明人： Masayuki Negoro , Ken Kawata
IPC分类号： C10M105/06
CPC分类号： C07D401/14 , C07D239/50 , C07D239/60 , C07D251/52 , C07D251/54 , C07D251/70 , C07D417/12 , C07D513/04 , C10M133/40 , C10M133/42 , C10M133/58 , C10M135/32
摘要： A lubricant composition containing a molecular complex compound formed by inter-molecular interaction of one or more keto-enol tautomeric compounds, wherein said molecular complex compound contains as a constituent a keto-enol tautomeric compound (but excluding specified triarylmelamine compounds) represented by the formula (I) (where, Q11 represents an oxygen atom, sulfur atom or N(R13); R11 to R13 independently represents a hydrogen atom or a substituent, at least one of which being a substituent containing a C4 or longer alkyl chain or oligoalkyleneoxy chain, a C2 or longer perfluoroalkyl chain, perfluoroalkyl ether chain or organic polysilyl chain; R11 and R12, or R11 and R13 may bind with each other-to thereby form a cyclic structure) is disclosed
摘要翻译：一种润滑剂组合物，其含有通过一种或多种酮 - 烯醇互变异构化合物的分子间相互作用形成的分子复合化合物，其中所述分子复合化合物含有由式（1）表示的酮 - 烯醇互变异构化合物（但不包括特定的三芳基三聚氰胺化合物）（I）（其中Q 11表示氧原子，硫原子或N（R 13）; R 11至R 11， 13个独立地表示氢原子或取代基，其中至少一个是含有C 4或更长的烷基链或低级亚烷基氧基的取代基，C 2 >或更长的全氟烷基链，全氟烷基醚链或有机聚硅烷基链; R 11和R 12，或R 11和R 13 可以彼此结合，从而形成循环结构）

25. 发明授权

US06987114B1 Antiviral pyrimidinedione derivatives and process for the preparation thereof 失效
标题翻译：抗病毒嘧啶二酮衍生物及其制备方法
公开(公告)号：US06987114B1
公开(公告)日：2006-01-17
申请号：US09719282
申请日：2000-04-08
申请人： Eui-Hwan Cho , Sun-Gan Chung , Sun-Hwan Lee , Ho-Seok Kwon , Jae-Eung Lee , Jeong-Ho Joo
发明人： Eui-Hwan Cho , Sun-Gan Chung , Sun-Hwan Lee , Ho-Seok Kwon , Jae-Eung Lee , Jeong-Ho Joo
IPC分类号： C07D239/54 , C07D239/60 , A61K31/513
CPC分类号： C07D239/54 , C07D239/60 , C07D401/06 , C07D403/06 , C07D405/06 , C07D413/06
摘要： The present invention relates to pyrimidinedione derivatives of following formula (I) which are useful as antiviral agents, especially as agents for treatment of AIDS, pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical compositions containing the same, wherein R represents cyclopropyl; cyclobutyl; cyclohexyl; unsubstituted or mono-, di- or trisubstituted phenyl with a group selected from hydroxy, C1–C4 alkyl, C1–C4 alkoxy, halogen, trifluoromethyl, cyano and amino; 1- or 2-naphthyl; 9-anthracenyl; 2-anthraquinonyl; unsubstituted or substituted pyridyl with a group selected from C1–C4 alkyl, C1–C4 alkoxy, cyano and halogen; 2-, 3- or 4-quinolinyl; oxiranyl; 1-benzotriazolyl; 2-benzoxazolyl; furanyl substituted with C1–C4 alkoxycarbonyl; C1–C4 alkylcarbonyl; or benzoyl, R1 represents halogen or C1–C4 alkyl, R2 and R3 represent independently hydrogen or C1–C4 alkyl, X represents oxygen atom, and Y represents oxygen atom, sulfur atom or carbonyl.
摘要翻译：本发明涉及下列通式（I）的嘧啶二酮衍生物，其可用作抗病毒剂，特别是作为治疗AIDS的药物，其药学上可接受的盐，其制备方法和含有该化合物的药物组合物，其中R代表环丙基; 环丁基环己基未取代的或具有选自羟基，C 1 -C 4 -C 4烷基，C 1 -C 3烷基的单 - ，二 - 或三取代苯基，烷氧基，卤素，三氟甲基，氰基和氨基; 1-或2-萘基; 9-蒽基; 2-蒽醌; 未取代或取代的具有选自C 1 -C 4烷基，C 1 -C 4烷氧基的基团的吡啶基，氰基和卤素; 2-，3-或4-喹啉基; 环氧乙烷基 1-苯并三唑基; 2-苯并恶唑基; 被C 1 -C 4烷氧基羰基取代的呋喃基; C 1 -C 4烷基羰基; 或苯甲酰基，R 1表示卤素或C 1 -C 4烷基，R 2和R 2， 3独立地表示氢或C 1 -C 4烷基，X表示氧原子，Y表示氧原子，硫原子或羰基。

26. 发明申请

US20060004030A1 Pyrimidine derivatives as modulators of chemokine receptor activity 失效
公开(公告)号：US20060004030A1
公开(公告)日：2006-01-05
申请号：US10525495
申请日：2003-08-20
申请人： Mark Ebden , Premji Meghani , Anthony Cook , John Steele , Lal Lashkar Cheema
发明人： Mark Ebden , Premji Meghani , Anthony Cook , John Steele , Lal Lashkar Cheema
IPC分类号： A61K31/513 , C07D43/02 , C07D239/46
CPC分类号： C07D239/56 , C07D239/60 , C07D401/04 , C07D401/12 , C07D403/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12
摘要： Compounds of formula (1), pharmaceutically acceptable salts, solvates and in vivo hydrolysable esters thereof, have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CXCR2) activity, and may be in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines.

27. 发明申请

US20050123831A1 Pentacyclic anion salts or tetrazapentalene derivatives and their uses as ionic conducting materials 有权
标题翻译：五环阴离子盐或四氮杂蒽衍生物及其用作离子导电材料
公开(公告)号：US20050123831A1
公开(公告)日：2005-06-09
申请号：US10926283
申请日：2004-08-25
申请人： Christophe Michot , Michel Armand , Michel Gauthier , Yves Choquette
发明人： Christophe Michot , Michel Armand , Michel Gauthier , Yves Choquette
IPC分类号： C07D233/58 , B01F1/00 , B01J31/02 , B01J31/04 , B01J31/06 , B01J31/12 , B01J31/18 , B01J31/22 , C01B31/02 , C04B41/83 , C07B37/02 , C07B37/12 , C07B41/06 , C07B61/00 , C07C45/46 , C07C45/69 , C07C67/00 , C07C255/05 , C07C255/10 , C07C255/13 , C07C255/17 , C07C255/27 , C07C255/31 , C07C255/46 , C07C255/65 , C07C257/14 , C07C309/80 , C07C311/03 , C07C311/04 , C07C311/09 , C07C311/48 , C07C317/04 , C07C317/08 , C07C317/14 , C07C317/22 , C07C317/24 , C07C317/34 , C07C317/44 , C07D207/44 , C07D207/452 , C07D213/76 , C07D219/10 , C07D231/18 , C07D233/56 , C07D233/90 , C07D239/60 , C07D241/46 , C07D241/48 , C07D249/04 , C07D249/08 , C07D249/10 , C07D249/12 , C07D251/66 , C07D251/70 , C07D253/06 , C07D277/64 , C07D277/82 , C07D279/20 , C07D285/00 , C07D285/12 , C07D285/125 , C07D285/135 , C07D285/15 , C07D285/16 , C07D303/34 , C07D303/36 , C07D307/54 , C07D307/64 , C07D311/52 , C07D311/58 , C07D311/72 , C07D311/80 , C07D311/82 , C07D319/06 , C07D333/16 , C07D333/20 , C07D333/24 , C07D405/06 , C07D407/04 , C07D409/12 , C07D417/10 , C07D417/14 , C07D487/22 , C07F1/02 , C07F1/06 , C07F7/10 , C07F7/18 , C07F9/6584 , C07F11/00 , C07F15/00 , C07F17/02 , C08F2/00 , C08F2/48 , C08F4/00 , C08F4/04 , C08F4/46 , C08F4/60 , C08F12/22 , C08F12/26 , C08F12/30 , C08F16/14 , C08F216/14 , C08F222/30 , C08F228/02 , C08G59/68 , C08G65/22 , C08G65/334 , C08G73/00 , C08G73/02 , C08G75/00 , C08G75/14 , C08G77/04 , C08G77/388 , C08G85/00 , C08J3/20 , C08J3/24 , C08J3/28 , C08J7/04 , C08L101/00 , C09B47/04 , C09B57/00 , C09B69/00 , C09B69/02 , C09B69/10 , C09C1/56 , C09C3/10 , C09D11/00 , C09K9/02 , C25B9/00 , G02F1/15 , H01B1/04 , H01B1/06 , H01B1/12 , H01B3/20 , H01G9/02 , H01G11/54 , H01M4/00 , H01M4/02 , H01M4/131 , H01M4/133 , H01M4/134 , H01M4/40 , H01M4/48 , H01M4/485 , H01M4/50 , H01M4/505 , H01M4/52 , H01M4/525 , H01M4/58 , H01M4/60 , H01M4/62 , H01M4/66 , H01M4/96 , H01M6/00 , H01M6/04 , H01M6/06 , H01M6/16 , H01M6/18 , H01M8/00 , H01M10/052 , H01M10/0525 , H01M10/0565 , H01M10/0567 , H01M10/0568 , H01M10/36 , H01B1/00
CPC分类号： B01J31/0224 , B01J31/0215 , B01J31/0222 , B01J31/0225 , B01J31/0227 , B01J31/0235 , B01J31/0239 , B01J31/0247 , B01J31/0251 , B01J31/0252 , B01J31/0267 , B01J31/0271 , B01J31/0281 , B01J31/0288 , B01J31/0289 , B01J31/04 , B01J31/06 , B01J31/068 , B01J31/124 , B01J31/1815 , B01J31/2208 , B01J2231/122 , B01J2231/14 , B01J2231/326 , B01J2231/341 , B01J2231/348 , B01J2231/4205 , B01J2231/543 , B01J2531/35 , B01J2531/824 , C07B37/02 , C07B37/12 , C07C45/46 , C07C45/69 , C07C67/00 , C07C255/10 , C07C255/17 , C07C255/27 , C07C255/46 , C07C255/65 , C07C257/14 , C07C311/03 , C07C311/04 , C07C311/09 , C07C311/48 , C07C317/04 , C07C317/08 , C07C317/14 , C07C317/22 , C07C317/24 , C07C317/34 , C07C317/44 , C07C2601/10 , C07C2602/42 , C07D207/452 , C07D213/76 , C07D219/10 , C07D231/18 , C07D233/90 , C07D239/60 , C07D241/42 , C07D249/04 , C07D249/10 , C07D249/12 , C07D251/70 , C07D277/64 , C07D277/82 , C07D285/125 , C07D285/135 , C07D285/15 , C07D285/16 , C07D303/34 , C07D307/54 , C07D307/64 , C07D311/52 , C07D311/58 , C07D311/82 , C07D319/06 , C07D333/16 , C07D333/24 , C07D405/06 , C07D409/12 , C07D417/10 , C07D417/14 , C07F17/02 , C08F4/04 , C08G65/3344 , C09B69/00 , C09B69/02 , C09B69/10 , G02F1/1525 , G02F2001/151 , H01B1/122 , H01B1/128 , H01G9/022 , H01G9/038 , H01G11/02 , H01G11/62 , H01M4/00 , H01M4/02 , H01M4/131 , H01M4/133 , H01M4/134 , H01M4/382 , H01M4/405 , H01M4/48 , H01M4/485 , H01M4/505 , H01M4/525 , H01M4/5815 , H01M4/5825 , H01M4/60 , H01M4/625 , H01M4/661 , H01M6/00 , H01M6/04 , H01M6/164 , H01M6/166 , H01M6/168 , H01M6/181 , H01M6/183 , H01M10/052 , H01M10/0525 , H01M10/0565 , H01M10/0567 , H01M10/0568 , Y02E60/13 , Y10S430/127 , Y10T29/49108 , Y10T428/2918 , C07C49/84 , C07C49/553
摘要： The invention relates to ionic compounds in which the anionic load has been delocalized. A compound disclosed by the invention includes an anionic portion combined with at least one cationic portion Mm+ in sufficient numbers to ensure overall electronic neutrality; the compound is further comprised of M as a hydroxonium, a nitrosonium NO+, an ammonium —NH4+, a metallic cation with the valence m, an organic cation with the valence m, or an organometallic cation with the valence m. The anionic load is carried by a pentacyclical nucleus of tetrazapentalene derivative bearing electroattractive substituents. The compounds can be used notably for ionic conducting materials, electronic conducting materials, colorant, and the catalysis of various chemical reactions.
摘要翻译：本发明涉及其中阴离子负荷已经离域的离子化合物。本发明公开的化合物包括足够数量的与至少一个阳离子部分M + H +结合的阴离子部分以确保整体电子中性; 该化合物进一步包含作为氢氧化物的M，亚硝酸铵，铵，铵，铵，价铵的金属阳离子 m，m价的有机阳离子或m价的有机金属阳离子。阴离子负载由带有电吸引取代基的四嗪基衍生物的五环核承载。这些化合物可以特别用于离子导电材料，电子导电材料，着色剂和各种化学反应的催化。

28. 发明申请

US20040097525A1 Novel Compounds 有权
标题翻译：新型化合物
公开(公告)号：US20040097525A1
公开(公告)日：2004-05-20
申请号：US10694561
申请日：2003-10-27
申请人： SmithKline Beecham plc
发明人： Deirdre Mary Bernadette Hickey , Robert John Ife , Colin Andrew Leach , Ivan Leo Pinto , Stephen Allan Smith , Steven James Stanway
IPC分类号： A61K031/519 , A61K031/517 , A61K031/513 , C07D487/02 , C07D239/72
CPC分类号： C07D239/56 , C07D239/60 , C07D239/70 , C07D239/95 , C07D401/12 , C07D403/12 , C07D495/04
摘要： Pyrimidone compounds of formula (I): 1 are inhibitors of the enzyme Lp-PLA2 and are of use is treating atheroscelerosis.
摘要翻译：式（I）的嘧啶酮化合物：是Lp-PLA2酶的抑制剂，并且可用于治疗动脉粥样硬化。

29. 发明授权

US06686369B1 &agr;-hydrdroxylic acid derivatives, their production and use 失效
标题翻译： α-羟基甲酸衍生物，其生产和使用
公开(公告)号：US06686369B1
公开(公告)日：2004-02-03
申请号：US09155944
申请日：1998-10-08
申请人： Dagmar Klinge , Wilhelm Amberg , Ernst Baumann , Andreas Kling , Hartmut Riechers , Liliane Unger , Manfred Raschack , Stefan Hergenröder , Sabine Schult
发明人： Dagmar Klinge , Wilhelm Amberg , Ernst Baumann , Andreas Kling , Hartmut Riechers , Liliane Unger , Manfred Raschack , Stefan Hergenröder , Sabine Schult
IPC分类号： C07D23960
CPC分类号： C07D217/22 , C07D239/34 , C07D239/48 , C07D239/52 , C07D239/56 , C07D239/60 , C07D239/80 , C07D239/96 , C07D251/20 , C07D251/22 , C07D251/30 , C07D251/38 , C07D251/52 , C07D471/04 , C07D487/04 , C07D491/04
摘要： The present invention relates to carboxylic acid derivatives of the formula where the radicals have the meanings stated in the description, to the preparation of these compounds and to their use as drugs.
摘要翻译：本发明涉及式的羧酸衍生物，其中自由基具有说明书中所述的含义，这些化合物的制备及其作为药物的用途。

30. 发明申请

US20040002123A1 Detection of transmembrane potentials by optical methods 有权
标题翻译：通过光学方法检测跨膜电位
公开(公告)号：US20040002123A1
公开(公告)日：2004-01-01
申请号：US10334288
申请日：2002-12-31
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： Roger Y. Tsien , Jesus E. Gonzalez III
IPC分类号： G01N033/53 , G01N033/567 , A01K067/033 , G06F019/00 , C07F005/00 , G01N033/50 , G01N033/48 , C07F009/547
CPC分类号： G01N33/502 , C07D209/08 , C07D215/227 , C07D239/60 , C07D239/62 , C07D239/66 , C07D239/80 , C07D241/44 , C07D265/36 , C07D279/16 , C07D311/16 , C07D487/04 , C07F5/003 , C07F5/02 , C07F5/027 , C07F9/10 , C07F9/5728 , C07K2319/033 , C09B23/02 , G01N33/5005 , G01N33/5008 , G01N33/5044 , G01N33/5058 , G01N33/5061 , G01N33/5076 , G01N33/52 , G01N33/542 , G01N33/582 , G01N33/6872 , G01N33/92 , G01N2405/04 , G01N2500/10 , Y10S436/80 , Y10S436/805
摘要： Methods and compositions are provided for detecting changes in membrane potential in membranes biological systems. In one aspect, the method comprises; a) providing a living cell with a first reagent comprising a charged hydrophobic molecule which is typically a fluorescence resonance energy transfer (FRET) acceptor or donor, or is a quencher and is capable of redistributing within the membrane of a biological membrane in response to changes in the potential across the membrane; b) providing the cell with a second reagent that can label the first face or the second face of a biological membrane within the cell; c) detecting light emission from the first reagent or the second reagent. One aspect of this method involves monitoring membrane potential changes in subcellular organelle membranes in a living cells. Another aspect of the invention is the use of certain embodiments of the method for the screening of test chemicals for activity to modulate the activity of a target ion channel. Another aspect of the present invention is a transgenic organism comprising a first reagent that comprises a charged hydrophobic fluorescent molecule, and a second reagent comprising a bioluminescent or naturally fluorescent protein.
摘要翻译：提供了用于检测膜生物系统中膜电位变化的方法和组合物。一方面，该方法包括： a）向活细胞提供包含通常为荧光共振能量转移（FRET）受体或供体的带电荷的疏水性分子的第一试剂，或者是猝灭剂，并且能够响应于变化而重新分布在生物膜的膜内在膜的潜力; b）向细胞提供可以标记细胞内生物膜的第一面或第二面的第二试剂; c）检测来自第一试剂或第二试剂的发光。该方法的一个方面涉及监测活细胞中亚细胞细胞器膜中的膜电位变化。本发明的另一方面是该方法的某些实施方案用于筛选测试化学品以调节靶离子通道的活性的活性。本发明的另一方面是转基因生物，其包含含有带电荷的疏水荧光分子的第一试剂和包含生物发光或天然荧光蛋白的第二试剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式